β-LactaMase
β-LactaMase structure
|
Common Name | β-LactaMase | ||
|---|---|---|---|---|
| CAS Number | 9073-60-3 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS08 |
Signal Word | Danger | |
|
A Novel Microbisporicin Producer Identified by Early Dereplication during Lantibiotic Screening.
Biomed Res. Int. 2015 , 419383, (2015) With the increasing need of effective antibiotics against multi-drug resistant pathogens, lantibiotics are an attractive option of a new class of molecules. They are ribosomally synthetized and posttranslationally modified peptides possessing potent antimicro... |
|
|
Identification of peptide inhibitors of penicillinase using a phage display library.
Anal. Biochem. 494 , 4-9, (2015) There is a constant need to identify novel inhibitors to combat β-lactamase-mediated antibiotic resistance. In this study, we identify three penicillinase-binding peptides, P1 (DHIHRSYRGEFD), P2 (NIYTTPWGSNWS), and P3 (SHSLPASADLRR), using a phage display lib... |
|
|
Outbreak of PER-1 and diversity of β-lactamases among ceftazidime-resistant Pseudomonas aeruginosa clinical isolates.
J. Med. Microbiol. 63(Pt 3) , 386-92, (2014) A growing number of β-lactamases have been reported in Pseudomonas aeruginosa clinical isolates. The aim of this study was to investigate the diversity of β-lactamases in the collection of 51 ceftazidime-resistant P. aeruginosa clinical isolates in four hospi... |
|
|
Comparative in-vitro activity of cefoperazone-tazobactam and cefoperazone-sulbactam combinations against ESBL pathogens in respiratory and urinary infections.
J. Assoc. Physicians India 60 , 22-4, (2012) The emergence and subsequent widespread dissemination of bacterial resistance to a variety of beta-lactam antibiotics by the elaboration of ESBL (Extended Spectrum Beta Lactamase) poses a serious threat to the effective use of beta lactam antibiotics and ceph... |
|
|
Looking for the new preparations for antibacterial therapy. II. Clinical trials; new beta-lactam antibiotics and beta-lactamase inhibitors.
Przegl. Epidemiol. 67(1) , 51-6, 135-40, (2013) To obtain a status of a medicinal product, a compound possessing potential antimicrobial activity and displaying no cytotoxicity, must undergo three phases of clinical trials to prove its therapeutic efficacy, safety and quality. Properties of the compound sh... |
|
|
[Fitness costs of blaNDM-1 bearing plasmid pNDM-BJ01 in Acinetobacter lwoffii].
Wei Sheng Wu Xue Bao 53(1) , 99-104, (2013) To investigate the fitness costs of the New Delhi Metallo-beta-lactamase-1 (bIaNDM-1) bearing plasmid pNDM-BJ01 in Acinetobacter lwoffii strain 10621, and to evaluate the potentials of the sustainahility and expansions among the Acinetobacter lwoffii populati... |
|
|
Successful medical treatment in a child with E. coli ESBL meningitis with acute communicating hydrocephalus and ventricular empyema: a case report.
J. Med. Assoc. Thai. 95 Suppl 12 , S138-41, (2012) Extended-spectrum beta-lactamase (ESBL) producing organisms cause wide spectrum of diseases including urinary tract infection, cholangitis, intra-abdominal abscess or pneumonia but rarely meningitis. The present report a successful nonsurgical, medical treatm... |
|
|
Notes from the field: hospital outbreak of carbapenem-resistant Klebsiella pneumoniae producing New Delhi metallo-beta-lactamase--Denver, Colorado, 2012.
MMWR Morb. Mortal. Wkly. Rep. 62(6) , 108, (2013) On August 16, 2012, the Colorado Department of Public Health and Environment was notified of two patients at an acute-care hospital in Denver with carbapenem-resistant Enterobacteriaceae (CRE), specifically Klebsiella pneumoniae (CRKP), isolated from respirat... |
|
|
The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
J. Assoc. Physicians India 60 , 28-30, (2012) In India where the prevalence of extended spectrum beta lactamase (ESBL) producing organisms among gram negative organisms is 60-70% and Ertapenem was unavailable at the beginning of this study, exclusive use of Group 2 Carbapenems (Imipenem and Meropenem) fo... |
|
|
Carbapenemase producing Enterobacteriaceae in Belgian nursing homes: myth or real danger?
Acta Clin. Belg. 69(1) , 30-2, (2014) Prevalence of carbapenemase-producing Enterobacteriaceae (CPE) is increasing both in hospitals and in the community. In this point prevalence study, rectal CPE colonization was investigated among 150 nursing home residents. No CPE were detected. Epidemiologic... |